{"id":"NCT03525574","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","officialTitle":"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-09","primaryCompletion":"2023-01-09","completion":"2023-01-09","firstPosted":"2018-05-15","resultsPosted":"2024-05-08","lastUpdate":"2024-05-08"},"enrollment":507,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"The study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation","primaryOutcome":{"measure":"Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From Day 1 up to Week 196","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":504,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":110,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Greece","Italy","Netherlands","Sweden","United Kingdom"]},"refs":{"pmids":["40209082","37983082","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":175,"n":506},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","COVID-19","Oropharyngeal pain"]}}